Predict your next investment

HEALTHCARE | Biotechnology
ateapharma.com

See what CB Insights has to offer

Founded Year

2012

Stage

IPO | IPO

Total Raised

$283.43M

Date of IPO

10/30/2020

About Atea Pharmaceuticals

Atea Pharmaceuticals (NASDAQ: AVIR) is a clinical-stage biopharmaceutical company that discovers and develops therapies to address the unmet medical needs of patients with life-threatening viral diseases.

Atea Pharmaceuticals Headquarter Location

125 Summer Street 16th Floor

Boston, Massachusetts, 02110,

United States

857-284-8891

Latest Atea Pharmaceuticals News

Atea Pharmaceuticals to Present at the 4th Annual Evercore ISI HealthCONx Conference

Nov 22, 2021

11/22/2021 | 07:01am EST Message : *Required fields BOSTON, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea, will participate in a virtual fireside chat at the 4th Annual Evercore ISI HealthCONx Conference on Wednesday, December 1, 2021 at 3:05 p.m. ET. A live webcast of the presentation will be available here and on the Company’s website at www.ateapharma.com. A replay of the webcast will be available for 90 days following the presentation. About Atea Pharmaceuticals Atea Pharmaceuticals is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing oral therapies to address the unmet medical needs of patients with life-threatening viral diseases. Leveraging the Company’s deep understanding of antiviral drug development, nucleos(t)ide chemistry, biology, biochemistry and virology, Atea has built a proprietary nucleotide prodrug platform to develop novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of severe viral diseases. Currently, Atea is focused on the development of orally-available, potent, and selective nucleotide prodrugs for difficult-to-treat, life-threatening viral infections, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, dengue virus, hepatitis C virus (HCV) and respiratory syncytial virus (RSV). For more information, please visit  www.ateapharma.com . Contacts

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Atea Pharmaceuticals

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Atea Pharmaceuticals in 1 CB Insights research brief, most recently on Jul 14, 2020.

Expert Collections containing Atea Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Atea Pharmaceuticals is included in 1 Expert Collection, including Biopharmaceuticals.

B

Biopharmaceuticals

14,140 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Atea Pharmaceuticals Patents

Atea Pharmaceuticals has filed 22 patents.

The 3 most popular patent topics include:

  • Carbamates
  • Cyclopropanes
  • Experimental drugs
patents chart

Application Date

Grant Date

Title

Related Topics

Status

3/5/2019

3/16/2021

Viral plant pathogens and diseases, Viral diseases, Hemorrhagic fevers, Animal virology, Animal viral diseases

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

3/5/2019

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

3/16/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Viral plant pathogens and diseases, Viral diseases, Hemorrhagic fevers, Animal virology, Animal viral diseases

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Atea Pharmaceuticals Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Atea Pharmaceuticals Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.